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Abstract
Objectives: To compare mortality rates for Indigenous and non-Indigenous 
Australians commencing renal replacement therapy (RRT) over time and 
by categories of remoteness of place of residence.
Design, setting and participants: An observational cohort study of 
Australia and New Zealand Dialysis and Transplant Registry (ANZDATA) 
data on Indigenous and non-Indigenous Australians registered with 
ANZDATA who commenced RRT from 1 January 1995 to 31 December 2009 
and were followed until 31 December 2011.
Main outcome measures: Five-year all-cause mortality for Indigenous and 
non-Indigenous patients in three cohorts (1995–1999, 2000–2004 and 
2005–2009) and five remoteness (of place of residence) categories. 
Results: Indigenous patients were younger, more likely to have diabetes, 
be referred late and be from a more remote area than non-Indigenous 
patients. Age and comorbid conditions increased with successive cohorts 
for both groups. Unadjusted analysis (using the log-rank test) showed 
an increased risk of death for Indigenous patients in the 1995–1999 
(P = 0.02) and 2000–2004 (P = 0.03) cohorts, but not for the 2005–2009 
cohort (P = 0.7). However, a Cox proportional hazards model adjusted 
for covariates (age, sex, late referral and comorbid conditions [diabetes, 
coronary artery disease, peripheral vascular disease, cerebrovascular 
disease, lung disease], and body mass index < 18.5 kg/m2 and > 30 kg/m2) 
showed the following Indigenous:non-Indigenous hazard ratios (with 95% 
CIs) for major capital cities: 1995–1999, 1.47 (1.21–1.79); 2000–2004, 1.35 
(1.12–1.63); and 2005–2009, 1.37 (1.14–1.66).
Conclusions: Although unadjusted analysis suggests that the survival 
gap between Indigenous and non-Indigenous patients receiving RRT has 
closed, there remains a significant disparity in survival after adjusting for the 
variables considered in our study.
Survival of Indigenous Australians receiving renal 
replacement therapy: closing the gap?
there remains 
a significant 
disparity in 
survival after 
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the variables 
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Aboriginal and Torres Strait Islander people (respect-fully referred to hereafter 
as Indigenous Australians) have a 
higher incidence of end-stage kidney 
disease requiring renal replacement 
therapy (RRT) than non-Indigenous 
Australians.1,2 A high proportion of 
Indigenous patients come from rural 
and remote areas,3 which are associ-
ated with markers of poorer socioeco-
nomic status.4 They are more likely to 
receive haemodialysis and much less 
likely to receive a kidney transplant 
than non-Indigenous Australians.1,5
In the past 10 years, there have been 
concerted efforts across Australia 
to provide dialysis services in more 
remote areas.6 While providing sup-
port for self-care home haemodialy-
sis and peritoneal dialysis in remote 
Australia has been challenging,7-9 
haemodialysis units supported by 
nurses have been established in 
small towns and communities. The 
impact of remoteness on quality of 
life for Indigenous RRT patients has 
been well described,10 but its effect 
on survival has not. We do know 
that there is a small increase in the 
risk of death associated with increas-
ing remoteness for non-Indigenous 
people receiving RRT.11
Emerging evidence in reports on 
the outcomes of RRT for Indigenous 
Australians suggests that there has 
been a significant gap in survival 
between Indigenous and non-Indi-
genous Australians in the past,12,13 but 
that this may have been narrowing.14 
Past studies have predated service 
delivery changes, concentrated on 
specific regions only12,15 or examined 
dialysis modalities and transplant 
survival separately16-18 rather than 
consider the outcome from the start 
of treatment for all patients regard-
less of their initial or subsequent RRT 
modality.
In this registry-based study, we 
sought to describe all-cause mor-
tality for Indigenous Australians 
commencing RRT over time, taking 
remoteness into account, and to 
compare this with all-cause mortal-
ity for non-Indigenous Australians 
commencing RRT.
Methods
Study population
The Australia and New Zealand 
Dialysis and Transplant Registry 
(ANZDATA) collects observational 
data on all patients receiving chronic 
RRT in Australia and New Zealand; 
these data are submitted by treating 
renal units. This study included all 
patients aged 15 years or more who 
commenced RRT between 1 January 
1995 and 31 December 2009 and who 
were maintained on RRT for more 
than 90 days to create three equal 
5-year period-inception cohorts 
(1995–1999, 2000–2004, 2005–2009, 
inclusive). Patients were followed un-
til 31 December 2011. We compared 
Indigenous Australians (those who 
self-identify as being of Aboriginal 
or Torres Strait Islander origin) with 
non-Indigenous Australians (includ-
ing those of any other ethnicity who 
commenced RRT in Australia).
Data collection
Comorbid conditions reported at 
commencement of RRT included 
coronary artery disease, peripheral 
vascular disease, cerebrovascular 
disease, chronic lung disease and 
diabetes. Comorbid conditions were 
recorded in three categories: no, yes 
or suspected. For this analysis, “no” 
and “suspected” were combined. 
Body mass index (BMI) was calcu-
lated from height and weight data at 
commencement of RRT. Late refer-
ral was defined as commencing RRT 
within 3 months of being referred to a 
nephrologist and data were collected 
from 1 April 1995.
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Postcode data at commencement of 
RRT were collected from 1 April 1995. 
An Australian Bureau of Statistics 
correspondence file19 was used to 
map postcodes onto the Accessibility 
and Remoteness Index of Australia 
(ARIA+), a system based on the physi-
cal distance by road from each location 
point to the nearest town or service 
centre. This creates a five-category 
classification of remoteness: major 
cities, inner regional, outer regional, 
remote and very remote areas.
Statistical analyses
The outcome for the study was all-
cause mortality. Patient data were 
censored at 5 years after commence-
ment of RRT, at the date of recovery 
of renal function or at the date of last 
known follow-up if they had not died 
previously.
The probability of survival to 5 years 
after the commencement of RRT was 
assessed by calculating Kaplan–
Meier failure curves20 with groups 
compared by the log-rank test.
Using the Cox proportional hazards 
(PH) model, analysis of the hazard 
of death was performed using inter-
action terms between Indigenous 
status and cohort, and Indigenous 
status and remoteness category. 
Variables were added to this model 
to determine which contributed most 
to the outcome of the final model. 
Explanatory variables included 
cohort, Indigenous status, age, sex, 
comorbid conditions, BMI catego-
ries, late referral and remoteness 
category. Interactions between vari-
ables thought likely based on know-
ledge of the literature were modelled; 
the difference in calculated effect on 
the hazard ratio was less than 20% 
for all those assessed. For all Cox 
PH models, the Efron method was 
used for resolving ties and the PH 
assumption was assessed by two dif-
ferent graphical means.21 Sensitivity 
analysis was conducted considering 
only confirmed comorbid conditions 
compared with both confirmed and 
suspected comorbid conditions com-
bined on the outcome of the full Cox 
PH model.
1  Characteristics of the whole population of 27 488 patients at first treatment, by time period and Indigenous status
1995–1999 (n = 6925) 2000–2004 (n = 9059) 2005–2009 (n = 11 504)
Characteristic
Non-Indigenous 
(n = 6321)
Indigenous 
(n = 604)
Non-Indigenous 
(n = 8232)
Indigenous 
(n = 827)
Non-Indigenous 
(n = 10 417)
Indigenous 
(n = 1087)
Male 3712 (58.7%) 254 (42.1%) 4983 (60.5%) 371 (44.9%) 6491 (62.3%) 481 (44.3%)
Mean (median) age 57.1 (60.4) years 48.5 (48.4) years 60.3 (63.6) years 50.9 (51.1) years 61.8 (64.5) years 51.0 (51.5 ) years
Median estimated glomerular 
filtration rate
5.3 mL/min/1.73m2 4.3 mL/min/1.73m2 5.8 mL/min/1.73m2 4.7 mL/min/1.73m2 7.1 mL/min/1.73m2 5.7 mL/min/1.73m2
Late referral 1338 (21.2%) 212 (35.1%) 1967 (23.9%) 303 (36.6%) 2217 (21.3%) 313 (28.8%)
Comorbid conditions
Diabetes 1696 (26.8%) 423 (70.0%) 2664 (32.4%) 643 (77.8%) 4177 (40.1%) 863 (79.4%)
Coronary 1826 (28.9%) 125 (20.7%) 2573 (31.3%) 225 (27.2%) 3627 (34.8%) 365 (33.6%)
Cerebrovascular 643 (10.1%) 37 (6.1%) 876 (10.6%) 84 (10.2%) 1309 (12.6%) 103 (9.5%)
Peripheral vascular 1204 (19.0%) 78 (12.9%) 1504 (18.3%) 189 (22.9%) 1966 (18.9%) 212 (19.5%)
Lung 666 (10.5%) 64 (10.6%) 922 (11.2%) 97 (11.7%) 1307 (12.5%) 134 (12.3%)
Body mass index (BMI)
Mean BMI 25.3 kg/m2 26.8 kg/m2 26.4 kg/m2 26.9 kg/m2 27.6 kg/m2 28.8 kg/m2
BMI < 18.5 kg/m2 (underweight) 340 (5.4%) 37 (6.1%) 346 (4.2%) 45 (5.4%) 350 (3.3%) 41 (3.8%)
BMI 18.5–30 kg/m2 5011 (79.3%) 410 (67.9%) 6101 (74.1%) 564 (68.2%) 7080 (68.0%) 636 (58.5%)
BMI > 30 kg/m2 (obese) 970 (15.3%) 157 (26.0%) 1785 (21.7%) 218 (26.4%) 2987 (28.7%) 410 (37.7%)
Remoteness classification
Major city 4572 (72.3%) 99 (16.4%) 5981 (72.7%) 108 (13.1%) 7428 (71.3%) 158 (14.5%)
Inner regional 1146 (18.1%) 60 (9.9%) 1560 (18.9%) 68 (8.2%) 2019 (19.4%) 101 (9.3%)
Outer regional 534 (8.5%) 186 (30.8%) 605 (7.4%) 268 (32.4%) 858 (8.2%) 277 (25.5%)
Remote 57 (0.9%) 97 (16.1%) 69 (0.8%) 172 (20.8%) 85 (0.8%) 199 (18.3%)
Very remote 12 (0.2%) 162 (26.8%) 17 (0.2%) 211 (25.5%) 27 (0.3%) 352 (32.4%)
Renal replacement therapy at 
start of treatment
Haemodialysis 4506 (71.3%) 501 (83.0%) 5904 (71.7%) 695 (84.0%) 7439 (71.4%) 887 (81.6%)
Peritoneal dialysis 1704 (27.0%) 102 (16.9%) 2090 (25.4%) 131 (15.8%) 2574 (24.7%) 198 (18.2%)
Transplant 111 (1.8%) 1 (0.2%) 238 (2.9%) 1 (0.1%) 404 (3.9%) 2 (0.2%)
Transplant by 5 years 1681 (26.6%) 84 (13.9%) 1941 (23.6%) 62 (7.5%) 2235 (21.5%)* 66 (6.1%)*
* Follow-up to 5 years not complete for the 2005–2009 cohort.  
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All analyses were conducted using 
Stata/MP4 12.1 (StataCorp). Approval 
for the study was granted by the 
combined Human Research Ethics 
Committee of the Northern Territory 
Department of Health & Menzies 
School of Health Research (HREC-
2011-1634); this process included an 
assessment by an Aboriginal ethics 
subcommittee with veto powers.
Results
Appendix 1 shows a flow chart of the 
study population and how the cohort 
of 27 488 patients available for study 
was derived. Baseline characteristics 
of the population available for study 
are outlined in Box 1, separated by 
cohort and Indigenous status. Data 
were censored for 78 patients at the 
date of recovery of renal function, 
and for 43 patients at the date of last 
known follow-up.
Indigenous patients commencing RRT 
were 10–12 years younger and more 
likely to be female and to have dia-
betes than non-Indigenous patients. 
Indigenous patients were more likely 
to have lower levels of endogenous 
kidney function at commencement 
of RRT, to be “late referred”, and to 
come from outer regional, remote or 
very remote regions than non-Indi-
genous patients. Far fewer Indigenous 
patients received kidney transplants 
in the first 5 years of treatment.
There were also important differ-
ences between cohorts for both 
Indigenous and non-Indigenous 
patients. Compared with the earli-
est cohort, patients in later cohorts 
were older, more likely to be male 
and more likely to have diabetes 
or coronary artery disease. Later 
cohorts also had a higher proportion 
of overweight and a lower proportion 
of underweight patients, and mean 
endogenous kidney function was 
higher. Of particular note, the rise 
in age for non-Indigenous patients 
was greater than that for Indigenous 
patients.
Years of follow-up, the number of 
deaths and the death rate for each 
cohort and patient group are shown 
in Box 2, and Kaplan–Meier failure 
curves are shown in Box 3. The log-
rank test confirmed a significant dif-
ference in the risk of death between 
Indigenous and non-Indigenous 
patients for 1995–1999 (P = 0.02) and 
2000–2004 (P = 0.03) but not for 2005–
2009 (P = 0.7).
A Cox PH model including only the 
main effects and interaction term 
between cohort and Indigenous sta-
tus showed a small increase in the 
hazard ratio for death for Indigenous 
compared with non-Indigenous 
patients in earlier cohorts but no 
difference in the 2005–2009 cohort 
(Appendix 2). A dramatically differ-
ent picture emerged once age was 
added to the model, with a greatly 
increased hazard ratio for Indigenous 
patients in all cohorts (Appendix 2). 
This second model also shows higher 
mortality rates for earlier cohorts 
compared with the 2005–2009 cohort 
of non-Indigenous patients.
This difference in mortality rates was 
attenuated but still clear in the fully 
adjusted Cox PH model that included 
all other comorbidity, late referral and 
remoteness terms (Box 4). There was 
no evidence of interaction by age or 
diabetes status or late referral on the 
relationship between Indigenous sta-
tus and mortality (data not shown). 
However, different categories of 
remoteness interacted with the rela-
tionship between Indigenous status 
and mortality to varying degrees.
Box 5 shows the impact of the 
Indigenous–cohort interaction on 
the mortality hazard. Adjusting for 
all other variables, the mortality risk 
improved for both non-Indigenous 
and Indigenous patients over time. 
However, the risk was higher in all 
cohorts for Indigenous compared 
with non-Indigenous patients in 
each remoteness category (Box 4): 
the cohort interaction terms were 
not statistically significant (χ 2 = 1.14; 
df = 2; P = 0.6).
The Indigenous–remoteness interac-
tion terms are highlighted in Box 6. 
Although non-Indigenous patients 
from major capital cities had a lower 
hazard than non-Indigenous patients 
from other regions, this was not the 
3  Kaplan–Meier failure curves of Indigenous versus 
non-Indigenous patients in the three cohorts 
receiving renal replacement therapy*
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* No censoring for transplantation.  
2  Years of follow-up, number of deaths and mortality rate for the whole cohort of 27 488 patients
1995–1999 (n = 6925) 2000–2004 (n = 9059) 2005–2009 (n = 11 504)
Variable
Non-Indigenous 
(n = 6321)
Indigenous 
(n = 604)
Non-Indigenous 
(n = 8232)
Indigenous 
(n = 827)
Non-Indigenous 
(n = 10 417)
Indigenous 
(n = 1087)
Cumulative years of follow-up 
(excluding first 90 days)
22 818.5 2103.6 29 201.4 2895.1 31 394.4 3348.2
Number of deaths 2772 294 3678 409 3660 381
Mortality rate (per 100 patient-
years)
12.15 13.98 12.59 14.13 11.66 11.38
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case for Indigenous patients (Box 4); 
however, the remoteness category 
interaction terms were not signifi-
cant overall (χ 2 = 6.17; df = 4; P = 0.2).
Discussion
In this analysis of all people com-
mencing RRT in Australia from 
1995 to 2009, we found that there 
was a survival difference between 
Indigenous and non-Indigenous pa-
tients in the past that appears to have 
closed more recently when assessed 
by methods without adjustment for 
the substantial differences in the pa-
tient populations.
With adjustment (particularly for 
age and diabetes), it became appar-
ent that survival for both Indigenous 
and non-Indigenous patients has 
indeed improved over time despite 
an increasing burden of comorbid 
conditions. However, the gap in 
survival between Indigenous and 
non-Indigenous patients has not 
narrowed.
The use of interaction terms allowed 
us to incorporate into one model 
factors of interest that may affect 
Indigenous and non-Indigenous 
patients differently. While increas-
ing the complexity of the analysis, 
this enabled us to explore how any 
disparity between Indigenous and 
non-Indigenous patients varies over 
time and remoteness categories. By 
doing so, we have shown not only 
that a difference in adjusted risk of 
death continues between Indigenous 
and non-Indigenous patients, but also 
that this difference has been main-
tained over the past 15 years in the 
face of improvements in both non-
Indigenous and Indigenous survival.
In addition, we have shown that 
that the relationship between 
remoteness category and mortality 
is different for Indigenous and non-
Indigenous patients. For all cohorts, 
an Indigenous patient from a major 
capital city had a greater risk of 
death than a similar non-Indigenous 
patient; differences for other regions 
are less apparent. The variation in 
the risk of death by remoteness for 
non-Indigenous patients remains 
similar to previously published 
findings.11 Despite efforts to provide 
dialysis treatments closer to home 
in recent years, the risk of death for 
Indigenous patients from very remote 
areas remains higher than for those 
in major cities (Box 6).
When interpreting the results of 
the fully adjusted Cox PH model, it 
is important to remember that the 
Indigenous and non-Indigenous 
patient populations remain quite 
different, and that they both have 
changed over the period studied. 
For example, while the hazard ratio 
for diabetes applies equally to both 
groups, up to 79.4% of Indigenous 
patients have diabetes compared 
with rates half that or less for non-
Indigenous patients. Similar differ-
ences exist for many other measured 
variables, particularly late refer-
ral (which remains more likely for 
Indigenous patients despite recent 
improvements) and age (which has 
become increasingly older in the 
non-Indigenous population over the 
period of the study) (Box 1).
4  Hazard ratios from fully adjusted Cox proportional hazards models 
for death by 5 years after starting renal replacement therapy
Variable Hazard ratio (95% CI)
Cohort*
1995–1999 (Indigenous:non-Indigenous) 1.47 (1.21–1.79)
2000–2004 (Indigenous:non-Indigenous) 1.35 (1.12–1.63)
2005–2009 (Indigenous:non-Indigenous) 1.37 (1.14–1.66)
Age (per year increase) 1.047 (1.045–1.049)
Sex (male:female) 0.89 (0.86–0.93)
Diabetes (yes:no) 1.44 (1.38–1.50)
Peripheral vascular disease (yes:no) 1.43 (1.37–1.50)
Cerebrovascular disease (yes:no) 1.26 (1.20–1.33)
Lung disease (yes:no) 1.36 (1.29–1.43)
Coronary artery disease (yes:no) 1.34 (1.29–1.40)
Body mass index < 18.5 kg/m2 (:18.5–30 kg/m2) 1.54 (1.42–1.69)
Body mass index > 30 kg/m2 (:18.5–30 kg/m2) 0.96 (0.92–1.01)
Late referral (yes:no) 1.27 (1.22–1.32)
Remoteness classification†
Major city (Indigenous:non-Indigenous) 1.37 (1.14–1.66)
Inner regional (Indigenous:non-Indigenous) 1.07 (0.86–1.34)
Outer regional (Indigenous:non-Indigenous) 1.08 (0.92–1.26)
Remote (Indigenous:non-Indigenous) 1.10 (0.84–1.43)
Very remote (Indigenous:non-Indigenous) 1.33 (0.82–2.11)
* The hazard ratio for each cohort for Indigenous compared with non-Indigenous patients is 
calculated as Indigenous status  cohort  Indigenous/cohort interaction term  Indigenous/
remoteness interaction term for major capital cities (Figure 2).
† The hazard ratio for each remoteness area for Indigenous compared with non-Indigenous 
patients is calculated as Indigenous status  remoteness classification  Indigenous/remoteness 
interaction term  Indigenous/cohort interaction term for 2005–2009 (Figure 3).  
5  Adjusted risk of death* for patients in the 
three cohorts living in major capital cities, by 
Indigenous status
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* Adjusted for age, sex, late referral and comorbid conditions (diabetes, 
coronary artery disease, peripheral vascular disease, cerebrovascular 
disease, lung disease) and body mass index < 18.5 kg/m2 and 
> 30 kg/m2.  
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There are clear differences between 
Indigenous and non-Indigenous 
patients in their likelihood of being 
treated with different RRT modalities, 
particularly kidney transplantation. 
The difference between Indigenous 
and non-Indigenous survival is 
smaller if transplantation is consid-
ered separately (data not shown), 
suggesting that the lower transplant 
rate for Indigenous patients may 
be contributing to their higher risk 
of death after starting RRT, poorer 
outcomes notwithstanding.16,17 Since 
fewer Indigenous patients receive 
transplants, it is reasonable to assume 
that those few who do are carefully 
selected and that those Indigenous 
patients remaining on dialysis will 
include a number who may well have 
had a transplant if they were non-
Indigenous. This latter group may 
have a better prognosis than other 
patients being treated by dialysis. 
To avoid this susceptibility bias, 
for our initial analysis, we assessed 
survival by pooling all patients 
together regardless of their initial 
or subsequent treatment modal-
ity, as was done in previous stud-
ies.22,23 Treatment modalities were 
not included as a term in any Cox 
PH models for the same reason. As 
a result, this study adds to previous 
work12-18 more recent data that are 
national in scope and encompass all 
RRT modalities.
The increased hazard for death 
for Indigenous patients receiving 
RRT, once other baseline variables 
recorded within ANZDATA are taken 
into consideration, requires explana-
tion. Of note, similar studies from 
overseas examining survival differ-
ences for people starting RRT have 
shown better adjusted survival rates 
for those from minority groups,23,24 
or at least equal survival in the 
case of aboriginal patients from the 
Prairie Provinces of Canada.22 Many 
Indigenous Australians receiving 
RRT come from more remote set-
tings than these overseas minority 
groups, but this does not explain 
the persistent increased hazard of 
death for Indigenous Australians 
from major capital cities. There may 
be different patterns of referral for 
RRT in different countries, although 
in all those quoted, the costs of RRT 
are covered by some form of national 
health insurance. The much lower 
likelihood of Indigenous Australian 
patients receiving a kidney trans-
plant compared with non-Indigenous 
Australians accounts for only some 
of the difference between the two 
groups.
There are limitations inherent in this 
study. Data on characteristics such as 
social and economic circumstances 
that may confound Indigenous status 
are not collected within ANZDATA 
and are challenging to tease out even 
with existing Australian Bureau of 
Statistics Census area data.25 It is pos-
sible that the recorded postcode of 
residence for Indigenous people is 
inaccurate.3 Comorbidity data cap-
tured in ANZDATA are imperfect, 
in part because they are based on 
the opinion of the treating physi-
cian rather than objectively defined 
criteria. There is also no information 
on the severity of comorbid condi-
tions. The analysis examined base-
line characteristics only, rather than 
changes in comorbidity over time. 
This approach was taken to provide 
useful information to clinicians dis-
cussing prognosis with patients con-
sidering RRT.
The improving underlying probabil-
ity of survival for both Indigenous 
and non-Indigenous patients start-
ing RRT, once recorded factors are 
considered, makes the use of these 
data for predicting survival patterns 
challenging. Nevertheless, it is sober-
ing to consider that the risk of death 
after starting RRT still outstrips that 
for many other diseases, including 
many cancers (Box 3). As a result, the 
highest priority must be to prevent 
as many people as possible (both 
Indigenous and non-Indigenous) 
from developing end-stage kidney 
disease in the first place.
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6  Adjusted risk of death* for remoteness areas for the 2005–2009 
cohort, by Indigenous status
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* Adjusted for age, sex, late referral and comorbid conditions (diabetes, coronary artery disease, 
peripheral vascular disease, cerebrovascular disease, lung disease) and body mass index 
< 18.5 kg/m2 and > 30 kg/m2.  
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